Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.38 |
| ▸ | KLK1 | P06870 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19263412 | 0.87 | KEAP1 (0.49) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL17540820 | 0.84 | POLB (0.54) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL9752787 | 0.80 | POLB (0.63) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL17229327 | 0.78 | POLB (0.50) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL16891381 | 0.76 | POLB (0.54) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL16891528 | 0.76 | MAPT (0.61) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL1768170 | 0.75 | POLB (0.61) | POLBNPSR1MAPT | |
| SCHEMBL16881026 | 0.74 | POLB (0.56) | KEAP1NFE2L2POLBNPSR1KLKB1 | |
| SCHEMBL4591947 | 0.74 | POLB (0.61) | POLBNPSR1KLKB1KLK1MAPT | |
| SCHEMBL1240350 | 0.74 | MAPT (0.56) | POLBNPSR1KLKB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | KEAP1 415/4885NFE2L2 2953/4885POLB 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.